DFE Pharma

DFE Pharma’s broad excipient portfolio includes starch, lactose and microcrystaline cellulose, with applications as, for example, inhalants and superdisintegrants. The company both manufactures excipients and partners with pharma companies to improve their product performance.

Corporate Head Office
DFE Pharma GmbH & Co KG
Klever Strasse 187
47568 Goch
Germany

Phone / Contact

T: +49 2823 928 877 0
F: +49 2823 928 877 99
E: [email protected]

Connect

DFE Pharma is a major global provider of excipients and excipient expertise. Its portfolio includes starch, lactose, microcrystalline cellulose (MCC), inhalants and superdisintegrants.

The company has production locations in the Netherlands, Germany, New Zealand and India, and sales offices in Germany, the US, Singapore, Japan, India, Brazil and China, and employs 360 people.

The DFE Pharma brand was formed in 2020 by the combination of DMV-Fonterra Excipients and DOMO-pharma. The company traces it roots back to 1900, to dairy producers in both the Netherlands and New Zealand. It is jointly owned by Royal FrieslandCampina, one of the world’s largest multinational dairy companies, and CVC Capital Partners, a leading global investor that acquired a 50% share.

Articles by DFE Pharma

Pauline Janssen

CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION

Pauline Janssen, discusses the various available devices for pulmonary delivery of medications, with a deeper dive into the challenges presented by replacing pMDI propellants with high global warming potential with new alternatives, or whether the optimal solution could be phasing out pMDIs in favour of DPIs.

COLLABORATION AIMS TO ACCELERATE DEVELOPMENT PROCESS IN DPI FORMULATION

Harry Peters explains how the collaboration between DFE Pharma, Hosokawa Micron and Harro Höfliger can help manufacturers save time and money in the development process for dry powder inhalers, enabling them to tackle unmet needs and unleash the potential of the significant market opportunity presented by dry powder inhalers.

TRANSFORMING DRUG DELIVERY WITH SYNERGISTIC WORKING

Bas van Driel discusses how expert collaborations can help develop a knowledge base to transform drug delivery and manufacturing. He shares how recent collaborative research projects involving lactose-based dry powder inhalation formulations, with and without magnesium stearate and lactose as an excipient in 3D tablet printing, have done just that.

PRACTICAL INSIGHTS INTO LACTOSE-BASED DPI FORMULATIONS, WITH & WITHOUT MAGNESIUM STEARATE

Partners DFE Pharma, Hosokawa Micron and Harro Höfliger describe their unique multidisciplinary study into lactose-based DPI formulations including magnesium stearate, whose findings will give generic players a head-start in the development process so that they can tap into this rapidly growing market. The three companies announce that they will be presenting the key insights from their research to interested parties during a joint webinar on the June 30th, 2020.

SELECTION OF EXCIPIENTS FOR DRY POWDER INHALERS

Harry Peters and Gerald Hebbink explain how, because dry powder inhalers need a carrier to help with ensuring the drug is effectively delivered, interest has been focused on developing inhalation-grade lactose for this purpose.

Top